london pharma

Hi all

As I have only recently returned to the HC EMS thread, I apologise if this has been posted previously.

There were some comments yesterday about Frank Timis and London Pharma/Proto Pharma.

Well here are some links regarding their involvement in the artimist project.

Of course I await any further info from the company, but if these contracts are pretty water tight regarding each party's obligations, and EMS have been funding it as required, I cant see any logical reason why the contractors would elect to breach their contractual obgliations.

Anyway....

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

http://www.franktimis.com/enterprise/london-pharma/

London Pharma


Frank provided seed capital for two pharmaceutical companies specialising in the efficient alternative delivery of certain types of drugs, specifically by sub-lingual (under the tongue) spray.

The first was ProtoPharma Ltd which was formed in 2005 to research and develop a better treatment for children with severe malaria. More than one million children die of malaria worldwide each year and Frank, who had been critically ill with cerebral malaria in 2004, saw his investment as a social responsibility initiative. The company is now conducting Phase Three trials in Africa using its patented ArTiMist spray, by which a formulation of the artemether drug is delivered sub-lingually to the child.

The scourge of malaria

According to the World Health Organisation, about half of the global population is at risk of contracting malaria with 250 million cases reported each year. Africa is the most vulnerable and at risk country and it is estimated that one in every five childhood diseases suffered in Africa is malaria, with one child dying every 30 seconds from the disease. It is a greater threat to the country then HIV, killing three times as many people.

ArTiMist is a multiple dose spray device for the treatment of malaria in young children and infants. The traditional anti-malaria treatment methods are pills and injections, which can be acceptable treatment delivery mechanisms for adults but cause complications in young children.

Tablets are difficult to administer if a patient is vomiting, suffering from diarrhoea or comatose. Injections need to be kept cool and rely on sufficient trained hospital staffs to inject the treatment, both of which are difficult in remote areas of Africa.

Children are also more susceptible to suffering from severe or complicated malaria, in which case time is a critical factor; complicated malaria can kill a child within 24 hours. The ArTiMist spray can be administered by untrained personnel immediately once the disease is suspected. Tests so far indicate it is up to three times more efficient as a treatment than conventional therapies because the artemether drug is delivered straight to the system without going through the gut.

ProtoPharma is also developing treatment of pregnant women and all adults using the same method.

Frank has also invested heavily in LondonPharma Ltd, founded in 2007 by the late Calvin Ross, founder of ProtoPharma. Using the experience gained from the sub-lingual delivery of artemether London Pharma is working on a number of important projects including the treatment of tumours, relief of severe pain and delivery of methadone for heroin addicts..

The Timis Corporation also supports the children?s ward at Centre de Sante Rwinkwavu, a clinic in Sierra Leone, helping to fight AIDS, tuberculosis and malaria.

Cavlin Ross, founder of both ProtoPharma and LondonPharma, died suddenly in August 2010. He said in 2009: ?I have known Frank Timis for four years and cannot speak highly enough of his excellent work in trying to help heroin addicts. He gave ?400,000 to fund research into a new treatment for these people.

?Frank has also helped me develop a new method of treatment for infants and children suffering from complicated malaria. In the fight to reduce this terrible toll, this would have not been possible without Mr Timis, who was prompted by his first hand experience of infants and children dying in Sierra Leone.?


>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

And here is a link on Artimist

http://www.franktimis.com/enterprise/london-pharma/artimist-spray/

ArTiMist Spray


According to the World Health Organisation, about half of the global population is at risk of contracting Malaria. 250 million cases are reported each year, resulting in one million deaths. Africa is the most vulnerable and at risk country in the world. It is estimated that one in every five childhood diseases suffered in Africa is Malaria, with one child dying every 30 seconds from the disease. It is a greater threat to the country then HIV, killing three times as many people.

ArTiMist is a multiple dose spray device for the treatment of Malaria in young children and infants. The traditional anti-Malaria treatment methods are pills and injections, which are acceptable treatment delivery mechanisms for adults but cause complications in young children.

Tablets are difficult to administer if a patient is vomiting, suffering from diarrhoea or comatose. Injections need to be kept cool and rely on sufficient trained hospital staffs to inject the treatment, both of which are difficult in remote areas of Africa.

Children are also more susceptible to suffering from severe or complicated Malaria, in which case time is a critical factor; complicated Malaria can kill a child within 24 hours. The ArTiMist spray can be administered by untrained personnel immediately once the disease is suspected. 99% of the medicine instantly enters the blood stream.

Recent clinical trials have been very encouraging and widespread use is expected before 2012.

The company is also developing designs to treat pregnant and elderly people using the same method.

London Pharma is also working on a number of other projects, including the development of a similar drug delivery mechanism to treat breast and brain cancers and administrate chemotherapy.

The Timis Corporation also supports the children?s ward at Centre de Sante Rwinkwavu, a clinic in Sierra Leone, helping to fight AIDS, Tuberculosis and Malaria.